325 related articles for article (PubMed ID: 32946450)
1. Age at diagnosis, glycemic trajectories, and responses to oral glucose-lowering drugs in type 2 diabetes in Hong Kong: A population-based observational study.
Ke C; Stukel TA; Shah BR; Lau E; Ma RC; So WY; Kong AP; Chow E; Chan JCN; Luk A
PLoS Med; 2020 Sep; 17(9):e1003316. PubMed ID: 32946450
[TBL] [Abstract][Full Text] [Related]
2. Obesity, clinical, and genetic predictors for glycemic progression in Chinese patients with type 2 diabetes: A cohort study using the Hong Kong Diabetes Register and Hong Kong Diabetes Biobank.
Jiang G; Luk AO; Tam CHT; Lau ES; Ozaki R; Chow EYK; Kong APS; Lim CKP; Lee KF; Siu SC; Hui G; Tsang CC; Lau KP; Leung JYY; Tsang MW; Kam G; Lau IT; Li JK; Yeung VT; Lau E; Lo S; Fung SKS; Cheng YL; Chow CC; Pearson ER; So WY; Chan JCN; Ma RCW; ;
PLoS Med; 2020 Jul; 17(7):e1003209. PubMed ID: 32722720
[TBL] [Abstract][Full Text] [Related]
3. Trends in Glucose-Lowering Drug Use, Glycemic Control, and Severe Hypoglycemia in Adults With Diabetes in Hong Kong, 2002-2016.
Yang A; Wu H; Lau ESH; Ma RCW; Kong APS; So WY; Luk AOY; Chan JCN; Chow E
Diabetes Care; 2020 Dec; 43(12):2967-2974. PubMed ID: 33046501
[TBL] [Abstract][Full Text] [Related]
4. Association of Hemoglobin A1c Levels With Use of Sulfonylureas, Dipeptidyl Peptidase 4 Inhibitors, and Thiazolidinediones in Patients With Type 2 Diabetes Treated With Metformin: Analysis From the Observational Health Data Sciences and Informatics Initiative.
Vashisht R; Jung K; Schuler A; Banda JM; Park RW; Jin S; Li L; Dudley JT; Johnson KW; Shervey MM; Xu H; Wu Y; Natrajan K; Hripcsak G; Jin P; Van Zandt M; Reckard A; Reich CG; Weaver J; Schuemie MJ; Ryan PB; Callahan A; Shah NH
JAMA Netw Open; 2018 Aug; 1(4):e181755. PubMed ID: 30646124
[TBL] [Abstract][Full Text] [Related]
5. Linagliptin plus metformin in patients with newly diagnosed type 2 diabetes and marked hyperglycemia.
Ross SA; Caballero AE; Del Prato S; Gallwitz B; Lewis-D'Agostino D; Bailes Z; Thiemann S; Patel S; Woerle HJ; von Eynatten M
Postgrad Med; 2016 Nov; 128(8):747-754. PubMed ID: 27684308
[TBL] [Abstract][Full Text] [Related]
6. Unmasking Fracture Risk in Type 2 Diabetes: The Association of Longitudinal Glycemic Hemoglobin Level and Medications.
Wang B; Wang Z; Poundarik AA; Zaki MJ; Bockman RS; Glicksberg BS; Nadkarni GN; Vashishth D
J Clin Endocrinol Metab; 2022 Mar; 107(4):e1390-e1401. PubMed ID: 34888676
[TBL] [Abstract][Full Text] [Related]
7. Sex Differences in Cardiovascular Effectiveness of Newer Glucose-Lowering Drugs Added to Metformin in Type 2 Diabetes Mellitus.
Raparelli V; Elharram M; Moura CS; Abrahamowicz M; Bernatsky S; Behlouli H; Pilote L
J Am Heart Assoc; 2020 Jan; 9(1):e012940. PubMed ID: 31902326
[TBL] [Abstract][Full Text] [Related]
8. Secondary failure of glycemic control for patients adding thiazolidinedione or sulfonylurea therapy to a metformin regimen.
Riedel AA; Heien H; Wogen J; Plauschinat CA
Am J Manag Care; 2007 Aug; 13(8):457-63. PubMed ID: 17685826
[TBL] [Abstract][Full Text] [Related]
9. Improved glycemic control with insulin glargine versus pioglitazone as add-on therapy to sulfonylurea or metformin in patients with uncontrolled type 2 diabetes mellitus.
Meneghini LF; Traylor L; Schwartz SL
Endocr Pract; 2010; 16(4):588-99. PubMed ID: 20350924
[TBL] [Abstract][Full Text] [Related]
10. Glycemic Improvement with a Fixed-dose combination of DPP-4 inhibitor + metformin in patients with Type 2 diabetes (GIFT study).
Bajaj HS; Ye C; Jain E; Venn K; Stein E; Aronson R
Diabetes Obes Metab; 2018 Jan; 20(1):195-199. PubMed ID: 28640433
[TBL] [Abstract][Full Text] [Related]
11. Trends in Drug Utilization, Glycemic Control, and Rates of Severe Hypoglycemia, 2006-2013.
Lipska KJ; Yao X; Herrin J; McCoy RG; Ross JS; Steinman MA; Inzucchi SE; Gill TM; Krumholz HM; Shah ND
Diabetes Care; 2017 Apr; 40(4):468-475. PubMed ID: 27659408
[TBL] [Abstract][Full Text] [Related]
12. Impact of rosiglitazone therapy on the lipid profile, glycemic control, and medication costs among type 2 diabetes patients.
Suh DC; Lee DH; McGuire M; Kim CM
Curr Med Res Opin; 2011 Aug; 27(8):1623-33. PubMed ID: 21696266
[TBL] [Abstract][Full Text] [Related]
13. Glycemic control continues to deteriorate after sulfonylureas are added to metformin among patients with type 2 diabetes.
Cook MN; Girman CJ; Stein PP; Alexander CM; Holman RR
Diabetes Care; 2005 May; 28(5):995-1000. PubMed ID: 15855556
[TBL] [Abstract][Full Text] [Related]
14. A comparative study of the effects of a dipeptidyl peptidase-IV inhibitor and sulfonylurea on glucose variability in patients with type 2 diabetes with inadequate glycemic control on metformin.
Kim HS; Shin JA; Lee SH; Kim ES; Cho JH; Son HY; Yoon KH
Diabetes Technol Ther; 2013 Oct; 15(10):810-6. PubMed ID: 24050737
[TBL] [Abstract][Full Text] [Related]
15. Excess Burden of Mental Illness and Hospitalization in Young-Onset Type 2 Diabetes: A Population-Based Cohort Study.
Ke C; Lau E; Shah BR; Stukel TA; Ma RC; So WY; Kong AP; Chow E; Clarke P; Goggins W; Chan JCN; Luk A
Ann Intern Med; 2019 Feb; 170(3):145-154. PubMed ID: 30641547
[TBL] [Abstract][Full Text] [Related]
16. Determinants of Glycemic Response to Add-On Therapy with a Dipeptidyl Peptidase-4 Inhibitor: A Retrospective Cohort Study Using a United Kingdom Primary Care Database.
Mamza J; Mehta R; Donnelly R; Idris I
Diabetes Technol Ther; 2016 Feb; 18(2):85-92. PubMed ID: 26752504
[TBL] [Abstract][Full Text] [Related]
17. Healthcare resource utilization after initiation of sodium-glucose co-transporter-2 inhibitors versus dipeptidyl peptidase-4 inhibitors or other glucose-lowering drugs in Japanese patients with type 2 diabetes.
Kohsaka S; Takeda M; Kidani Y; Yajima T
Diabetes Obes Metab; 2021 Apr; 23 Suppl 2():28-39. PubMed ID: 33835640
[TBL] [Abstract][Full Text] [Related]
18. Combination therapy with insulin glargine plus metformin but not insulin glargine plus sulfonylurea provides similar glycemic control to triple oral combination therapy in patients with type 2 diabetes uncontrolled with dual oral agent therapy.
Hollander P; Sugimoto D; Vlajnic A; Kilo C
J Diabetes Complications; 2015; 29(8):1266-71. PubMed ID: 26281972
[TBL] [Abstract][Full Text] [Related]
19. Efficacy and safety of the dipeptidyl peptidase-4 inhibitor sitagliptin added to ongoing metformin therapy in patients with type 2 diabetes inadequately controlled with metformin alone.
Charbonnel B; Karasik A; Liu J; Wu M; Meininger G;
Diabetes Care; 2006 Dec; 29(12):2638-43. PubMed ID: 17130197
[TBL] [Abstract][Full Text] [Related]
20. Glycemic Efficacy and Metabolic Consequences of an Empagliflozin Add-on versus Conventional Dose-Increasing Strategy in Patients with Type 2 Diabetes Inadequately Controlled by Metformin and Sulfonylurea.
Shin Y; Moon JH; Chin HJ; Ferrannini E; Lim S
Endocrinol Metab (Seoul); 2020 Jun; 35(2):329-338. PubMed ID: 32615717
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
